BACKGROUND: We and others have shown that primary hepatitis C (HCV) infection in men infected with human immunodeficiency virus (HIV) causes early-onset liver fibrosis; however, little is known about the long-term natural history of the liver disease in these HIV-infected men. METHODS: We followed a cohort of HIV-infected men with primary HCV infection in New York City. RESULTS: Four men who were not cured after their primary HCV infection developed decompensated cirrhosis within 17 months to 6 years after primary HCV infection. Three died within 8 years of primary HCV infection, and 1 survived after liver transplant done 2 years after primary HCV infection. Three of the 4 men had AIDS at the time of primary HCV infection, and the most rapid progression occurred in the 2 men with the lowest CD4 counts at the time of HCV infection. Liver histopathology was most consistent with HCV-induced damage even though some had exposures to other potential hepatotoxins. CONCLUSIONS: Primary HCV infection resulted in decompensated cirrhosis and death within 2-8 years in 4 HIV-infected men. The rapid onset of fibrosis due to primary HCV infection in HIV-infected men cannot therefore be considered benign. The rate of continued progression to liver failure may be proportional to the degree of underlying immunocompromise caused by HIV infection. More research is needed to better define the mechanisms behind accelerated liver damage.
BACKGROUND: We and others have shown that primary hepatitis C (HCV) infection in men infected with human immunodeficiency virus (HIV) causes early-onset liver fibrosis; however, little is known about the long-term natural history of the liver disease in these HIV-infectedmen. METHODS: We followed a cohort of HIV-infectedmen with primary HCV infection in New York City. RESULTS: Four men who were not cured after their primary HCV infection developed decompensated cirrhosis within 17 months to 6 years after primary HCV infection. Three died within 8 years of primary HCV infection, and 1 survived after liver transplant done 2 years after primary HCV infection. Three of the 4 men had AIDS at the time of primary HCV infection, and the most rapid progression occurred in the 2 men with the lowest CD4 counts at the time of HCV infection. Liver histopathology was most consistent with HCV-induced damage even though some had exposures to other potential hepatotoxins. CONCLUSIONS:Primary HCV infection resulted in decompensated cirrhosis and death within 2-8 years in 4 HIV-infectedmen. The rapid onset of fibrosis due to primary HCV infection in HIV-infectedmen cannot therefore be considered benign. The rate of continued progression to liver failure may be proportional to the degree of underlying immunocompromise caused by HIV infection. More research is needed to better define the mechanisms behind accelerated liver damage.
Authors: Ivana Maida; Marina Núñez; Maria Jose Ríos; Luz Martín-Carbonero; Giovanni Sotgiu; Carlos Toro; Pablo Rivas; Pablo Barreiro; Maria Stella Mura; Sergio Babudieri; Javier Garcia-Samaniego; Juan González-Lahoz; Vincent Soriano Journal: J Acquir Immune Defic Syndr Date: 2006-06 Impact factor: 3.731
Authors: Gabriel Chamie; Maurizio Bonacini; David R Bangsberg; Jack T Stapleton; Christopher Hall; E Turner Overton; Rebecca Scherzer; Phyllis C Tien Journal: Clin Infect Dis Date: 2007-01-10 Impact factor: 9.079
Authors: María López-Diéguez; María L Montes; José F Pascual-Pareja; Carmen Quereda; Miguel A Von Wichmann; Juan Berenguer; Cristina Tural; Asunción Hernando; Juan González-García; Lucia Serrano; José R Arribas Journal: AIDS Date: 2011-04-24 Impact factor: 4.177
Authors: Daniel S Fierer; Alison J Uriel; Damaris C Carriero; Arielle Klepper; Douglas T Dieterich; Michael P Mullen; Swan N Thung; M Isabel Fiel; Andrea D Branch Journal: J Infect Dis Date: 2008-09-01 Impact factor: 5.226
Authors: Thijis van de Laar; Oliver Pybus; Sylvia Bruisten; David Brown; Mark Nelson; Sanjay Bhagani; Martin Vogel; Alex Baumgarten; Marie-Laure Chaix; Martin Fisher; Hannelore Gotz; Gail V Matthews; Stefan Neifer; Peter White; William Rawlinson; Stanislav Pol; Jurgen Rockstroh; Roel Coutinho; Greg J Dore; Geoffrey M Dusheiko; M Danta Journal: Gastroenterology Date: 2009-05 Impact factor: 22.682
Authors: Marija Zeremski; Rositsa B Dimova; Jaroslaw Pillardy; Ype P de Jong; Ira M Jacobson; Andrew H Talal Journal: J Infect Dis Date: 2016-08-02 Impact factor: 5.226
Authors: Daniel S Fierer; Douglas T Dieterich; Michael P Mullen; Andrea D Branch; Alison J Uriel; Damaris C Carriero; Wouter O van Seggelen; Rosanne M Hijdra; David G Cassagnol Journal: Clin Infect Dis Date: 2013-12-13 Impact factor: 9.079
Authors: Audrey L French; Jonathan W Martin; Charlesnika T Evans; Marion Peters; Seble G Kessaye; Marek Nowicki; Mark Kuniholm; Elizabeth Golub; Michael Augenbraun; Seema N Desai Journal: J Acquir Immune Defic Syndr Date: 2017-12-01 Impact factor: 3.731
Authors: Daniela K van Santen; Jannie J van der Helm; Giota Touloumi; Nikos Pantazis; Roberto Muga; Barbara Gunsenheimer-Bartmeyer; M John Gill; Eduard Sanders; Anthony Kelleher; Robert Zangerle; Kholoud Porter; Maria Prins; Ronald B Geskus Journal: AIDS Date: 2019-02-01 Impact factor: 4.177